From Insight to Impact: Strategic Growth Mapping in the Nontuberculous Mycobacterial Infection Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Nontuberculous Mycobacterial Infection Market Growth Performance Trended Historically, And What Lies Ahead?
In recent times, the market size of nontuberculous mycobacterial infection has observed steady growth. Forecasts predict that its value will increase from $14.25 billion in 2024 to $14.96 billion in 2025, representing a compound annual growth rate (CAGR) of 5.0%. Factors such as enhanced diagnostics, an aging population, increased awareness of cystic fibrosis, and the use of immunosuppressive drugs are believed to have contributed to this notable growth during the historic period.
The market size for nontuberculous mycobacterial infection is anticipated to witness significant expansion in the upcoming years. It is projected to reach$19.37 billion in 2029″ with a compound annual growth rate (CAGR) of 6.7%. The escalated growth during the forecast period can be accredited to the development of antimicrobial drugs, increased awareness about ntm, advancements in genetic research, and the spread of telehealth and remote monitoring. The forecast period is also expected to witness major trends like personalized treatment, regulatory focus, combination therapies, and the utilisation of digital health resources.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
What are the Fundamental Drivers and Innovations Shaping the Nontuberculous Mycobacterial Infection Market?
The projected growth of the nontuberculous mycobacterial infection market is largely driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD). COPD is a long-term respiratory ailment identified by consistent and often escalating lung airflow restriction. The presence of nontuberculous mycobacterial (NTM) infections tends to be more detrimental to COPD patients, causing a significant drop in forced expiratory volume in one second (FEV1) and an escalated exacerbation rate. The vulnerability of the immune system and the damage to lung tissue due to COPD can make it more susceptible to NTM bacterial infections. For example, a report by The Scottish Public Health Observatory (ScotPHO) in March 2023 revealed a steady increase in COPD rates between 2021 and 2022, with the male incidence rate rising from 83.2 to 97.6 per 100,000 persons and the female rate from 72.6 to 97.3. Hence, the escalating occurrence of COPD is observed to be a key driver in the growth of the nontuberculous mycobacterial infection market.
How Is the Nontuberculous Mycobacterial Infection Market Segmented?
The nontuberculous mycobacterial infectionmarket covered in this report is segmented –
1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin; Clarithromycin
2) By Rifampin: Rifampin; Rifabutin
3) By Aminoglycoside: Amikacin; Streptomycin
4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp
Which Regions Are Driving the Next Phase of the Nontuberculous Mycobacterial Infection Market Growth?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Trends Are Shaping the Future of the Nontuberculous Mycobacterial Infection Market?
Leading firms in the nontuberculous mycobacterial infection market have adopted innovative approval techniques such as fast track designation for the authorization of drugs to maintain their market stature. The Fast Track designation from the FDA is a specifically designed process to accelerate both the development and review phases of drugs targeted at serious illnesses with a considerable void in medical amenities. For example, in July 2022, the U.S. federal agency, the Food and Drug Administration, granted NUZYRA Fast Track Designation to handle nontuberculous mycobacterial (NTM) lung disease due to Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is a uniquely-developed broad-spectrum antibiotic reserved for treating severe bacterial infections, including the ones caused by resistant strains. This particular designation speeds up the development and review procedures of the NUZYRA antibiotic, addressing considerable unmet medical requirements.
View the full report here:
How Is the Nontuberculous Mycobacterial Infection Market Defined and What Are Its Core Parameters?
A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
